Details of the Drug

General Information of Drug (ID: DM6WJO9)

Drug Name
Etodolac
Synonyms
etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Etodolacum; Etodolaco; Ramodar; AY 24236; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; AY-24236; AY-24,236; Edolan; CCRIS 3923; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; CHEMBL622; NSC 282126; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Approved [1], [2]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 287.35
Topological Polar Surface Area (xlogp) 2.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The apparent oral clearance of drug is 49.1 mL/h/kg [5]
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.3 - 10.3 hours [6]
Metabolism
The drug is metabolized via the liver [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 69.6 micromolar/kg/day [8]
Vd
The volume of distribution (Vd) of drug is 0.39 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.01 mg/mL [3]
Chemical Identifiers
Formula
C17H21NO3
IUPAC Name
2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
Canonical SMILES
CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O
InChI
InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
InChIKey
NNYBQONXHNTVIJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3308
ChEBI ID
CHEBI:4909
CAS Number
41340-25-4
DrugBank ID
DB00749
TTD ID
D0N1WU
VARIDT ID
DR00648
INTEDE ID
DR0666
ACDINA ID
D00257

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [9], [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [11]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A10 (UGT1A10) DEL5N6Y UD110_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pain
ICD Disease Classification MG30-MG3Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.10E-01 -5.91E-02 -3.60E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Etodolac
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Aspirin. Pain [MG30-MG3Z] [64]
Coadministration of a Drug Treating the Disease Different from Etodolac (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [65]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Etodolac and Repaglinide. Acute diabete complication [5A2Y] [66]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Etodolac and Glibenclamide. Acute diabete complication [5A2Y] [66]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Etodolac and Tolazamide. Acute diabete complication [5A2Y] [66]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Etodolac and Glipizide. Acute diabete complication [5A2Y] [66]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Etodolac and Inotersen. Amyloidosis [5D00] [67]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [68]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Budesonide. Asthma [CA23] [69]
Ofloxacin DM0VQN3 Moderate Additive CNS depression effects by the combination of Etodolac and Ofloxacin. Bacterial infection [1A00-1C4Z] [70]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Kanamycin. Bacterial infection [1A00-1C4Z] [71]
Sparfloxacin DMB4HCT Moderate Additive CNS depression effects by the combination of Etodolac and Sparfloxacin. Bacterial infection [1A00-1C4Z] [70]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Streptomycin. Bacterial infection [1A00-1C4Z] [71]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Etodolac and Gemifloxacin. Bacterial infection [1A00-1C4Z] [70]
Norfloxacin DMIZ6W2 Moderate Additive CNS depression effects by the combination of Etodolac and Norfloxacin. Bacterial infection [1A00-1C4Z] [70]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Etodolac and ABT-492. Bacterial infection [1A00-1C4Z] [70]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Gentamicin. Bacterial infection [1A00-1C4Z] [71]
Levofloxacin DMS60RB Moderate Additive CNS depression effects by the combination of Etodolac and Levofloxacin. Bacterial infection [1A00-1C4Z] [70]
Lomefloxacin DMVRH9C Moderate Additive CNS depression effects by the combination of Etodolac and Lomefloxacin. Bacterial infection [1A00-1C4Z] [70]
Etidronic acid DM1XHYJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Etidronic acid. Bone paget disease [FB85] [72]
Risedronate DM5FLTY Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Risedronate. Bone paget disease [FB85] [72]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Etodolac and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [73]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Etodolac and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [74]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Etodolac and Iodipamide. Cholelithiasis [DC11] [75]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Etodolac and Regorafenib. Colorectal cancer [2B91] [67]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Etodolac and Drospirenone. Contraceptive management [QA21] [76]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Methoxyflurane. Corneal disease [9A76-9A78] [67]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Etodolac and Ardeparin. Coronary thrombosis [BA43] [77]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Etodolac and Danaparoid. Deep vein thrombosis [BD71] [77]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Etodolac and Rivaroxaban. Deep vein thrombosis [BD71] [78]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Etodolac and Sertraline. Depression [6A70-6A7Z] [79]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Etodolac and Vilazodone. Depression [6A70-6A7Z] [79]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Etodolac and Vortioxetine. Depression [6A70-6A7Z] [79]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Etodolac and Milnacipran. Depression [6A70-6A7Z] [79]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Etodolac and Escitalopram. Depression [6A70-6A7Z] [79]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Etodolac and Desvenlafaxine. Depression [6A70-6A7Z] [79]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Etodolac and Clomipramine. Depression [6A70-6A7Z] [79]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Etodolac and PMID28870136-Compound-49. Discovery agent [N.A.] [80]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Cannabidiol. Epileptic encephalopathy [8A62] [67]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Etodolac when combined with Ethacrynic acid. Essential hypertension [BA00] [81]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Etodolac and Tazemetostat. Follicular lymphoma [2A80] [74]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Etodolac and Avapritinib. Gastrointestinal stromal tumour [2B5B] [67]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Etodolac and Sulfinpyrazone. Gout [FA25] [74]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Etodolac when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [81]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Etodolac when combined with Bumetanide. Heart failure [BD10-BD1Z] [81]
Hydroflumethiazide DMVPUQI Moderate Antagonize the effect of Etodolac when combined with Hydroflumethiazide. Heart failure [BD10-BD1Z] [81]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Brentuximab vedotin. Hodgkin lymphoma [2B30] [82]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Etodolac and Mipomersen. Hyper-lipoproteinaemia [5C80] [83]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Etodolac and Teriflunomide. Hyper-lipoproteinaemia [5C80] [84]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Etodolac and BMS-201038. Hyper-lipoproteinaemia [5C80] [85]
Indapamide DMGN1PW Moderate Antagonize the effect of Etodolac when combined with Indapamide. Hypertension [BA00-BA04] [81]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Etodolac when combined with Trichlormethiazide. Hypertension [BA00-BA04] [81]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Etodolac and Dipyridamole. Hypertension [BA00-BA04] [74]
Potassium chloride DMMTAJC Moderate Increased risk of hyperkalemia by the combination of Etodolac and Potassium chloride. Hypo-kalaemia [5C77] [86]
Balsalazide DMO091F Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Balsalazide. Indeterminate colitis [DD72] [87]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Etodolac and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [88]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Idelalisib. Mature B-cell leukaemia [2A82] [89]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Etodolac and Acalabrutinib. Mature B-cell lymphoma [2A85] [90]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Etodolac and Ponatinib. Mature B-cell lymphoma [2A85] [91]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Etodolac and Exjade. Mineral absorption/transport disorder [5C64] [92]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Etodolac and Panobinostat. Multiple myeloma [2A83] [65]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Deflazacort. Muscular dystrophy [8C70] [69]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Etodolac and Ruxolitinib. Myeloproliferative neoplasm [2A20] [74]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Etodolac and Dasatinib. Myeloproliferative neoplasm [2A20] [93]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Etodolac and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [94]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Etodolac and Prasugrel. Myocardial infarction [BA41-BA43] [67]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Etodolac and Vorapaxar. Myocardial infarction [BA41-BA43] [95]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Etodolac and Tirofiban. Myocardial infarction [BA41-BA43] [96]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Etodolac and Dexfenfluramine. Obesity [5B80-5B81] [79]
Polythiazide DMCH80F Moderate Antagonize the effect of Etodolac when combined with Polythiazide. Oedema [MG29] [81]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Etodolac and MK-4827. Ovarian cancer [2C73] [67]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Etodolac and Epoprostenol. Pulmonary hypertension [BB01] [97]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Etodolac and Iloprost. Pulmonary hypertension [BB01] [97]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Etodolac and Everolimus. Renal cell carcinoma [2C90] [98]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Etodolac and Temsirolimus. Renal cell carcinoma [2C90] [98]
Gatifloxacin DMSL679 Moderate Additive CNS depression effects by the combination of Etodolac and Gatifloxacin. Respiratory infection [CA07-CA4Z] [70]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Sulfasalazine. Rheumatoid arthritis [FA20] [87]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Dexamethasone. Rheumatoid arthritis [FA20] [69]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Etodolac and Leflunomide. Rheumatoid arthritis [FA20] [84]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [69]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [67]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [69]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Pitolisant. Somnolence [MG42] [67]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Etodolac and Caplacizumab. Thrombocytopenia [3B64] [74]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Etodolac and Apixaban. Thrombosis [DB61-GB90] [67]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Etodolac and Cangrelor. Thrombosis [DB61-GB90] [74]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Etodolac and Brilinta. Thrombosis [DB61-GB90] [67]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Etodolac and Cabozantinib. Thyroid cancer [2D10] [99]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Etodolac and Sirolimus. Transplant rejection [NE84] [98]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Etodolac and Tacrolimus. Transplant rejection [NE84] [98]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Olsalazine. Ulcerative colitis [DD71] [87]
Cinoxacin DM4EWNS Moderate Additive CNS depression effects by the combination of Etodolac and Cinoxacin. Urinary tract infection [GC08] [70]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Plazomicin. Urinary tract infection [GC08] [71]
Nalidixic acid DMRM0JV Moderate Additive CNS depression effects by the combination of Etodolac and Nalidixic acid. Urinary tract infection [GC08] [70]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Etodolac and Betrixaban. Venous thromboembolism [BD72] [100]
⏷ Show the Full List of 94 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Calcium hydrogenphosphate E00294 24441 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Disodium hydrogenorthophosphate E00283 24203 Buffering agent; Complexing agent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 36 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Etodolac 200 mg capsule 200 mg Oral Capsule Oral
Etodolac 300 mg capsule 300 mg Oral Capsule Oral
Etodolac 600 mg tablet 600 mg 24 HR Extended Release Oral Tablet Oral
Etodolac 500 mg tablet 500 mg 24 HR Extended Release Oral Tablet Oral
Etodolac 400 mg tablet 400 mg 24 HR Extended Release Oral Tablet Oral
Etodolac 400 mg tablet 400 mg Oral Tablet Oral
Etodolac 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7185).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074819.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
10 Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol. 2001 Jul;8(7):S35-9.
11 Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004 May;34(5):449-61.
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
14 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
15 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
16 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
17 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
18 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
19 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
20 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
21 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
22 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
23 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
24 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
25 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
26 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
27 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
28 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
29 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
30 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
31 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
32 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
33 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
34 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
35 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
36 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
37 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
38 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
39 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
40 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
41 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
42 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
43 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
44 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
45 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
46 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
47 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
48 Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
49 UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
50 [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.
51 S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
52 Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
53 In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos. 2010 Sep;38(9):1471-9.
54 UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 Apr;106(1):97-132.
55 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
56 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
57 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
58 Pfizer. Product Development Pipeline. March 31 2009.
59 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
60 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
61 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
62 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
63 Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
64 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
65 Cerner Multum, Inc. "Australian Product Information.".
66 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
67 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
68 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
69 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
70 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
71 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
72 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
73 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
74 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
75 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
76 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
77 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
78 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
79 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
80 Canadian Pharmacists Association.
81 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
82 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
83 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
84 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
85 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
86 Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
87 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
88 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
89 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
90 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
91 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
92 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
93 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
94 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
95 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
96 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
97 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
98 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
99 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
100 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.